The DOI matches its Crossref record; the references it cites are not checked yet.
Brolucizumab and immunogenicity
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several reports have postulated either a type III or type IV hypersensitivity reaction for brolucizumab-associated vasculitis.
“Several reports have postulated either a type III or type IV hypersensitivity reaction [38, 79].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 10 · Cited by 51
Metadata
- Authors
- Sharma, A., Kumar, N., Parachuri, N., Sharma, R., Bandello, F., Kuppermann, B. D., & Loewenstein, A.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Corresponding author
- Sharma, Ashish
- Venue
- Eye
- Published
- 2020-04-06
- Volume
- 34
- Issue
- 10
- Pages
- 1726-1728
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC7608337
- OpenAlex
- W3015150367
- Cited by
- 51
- References
- 10
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 10 · 2021: 16 · 2020: 3
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Eye (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- brolucizumab, immunogenicity, anti-VEGF therapy, neovascular age-related macular degeneration, intravitreal injection, endophthalmitis, ocular inflammation, post-translational modification, biosimilars, nocebo effect, aflibercept, ranibizumab
- MeSH terms
- Humans, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
